Cheila Rocha
University of Lisbon
24 Papers
185 Citations
Cheila Rocha is an academic researcher from University of Lisbon. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 12 publications. Previous affiliations of Cheila Rocha include Instituto Superior de Ciências da Saúde Egas Moniz & Instituto de Medicina Molecular.
Chat about Author
Papers
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
Prerna Arora,Lu Zhang,Cheila Rocha,Anzhalika Sidarovich,Amy Kempf,Sebastian R. Schulz,Anne Cossmann,Bernhard Manger,Eva Baier,Björn Tampe,Onnen Moerer,Steffen Dickel,Alexandra Dopfer-Jablonka,Hans-Martin Jäck,Georg M. N. Behrens,Martin Sebastian Winkler,Stefan Pöhlmann,Markus Hoffmann +17 more
- 01 Apr 2022
TL;DR: The results show that all presently circulating omicron subvariants evade neutralisation by vaccine-induced antibodies with comparably high efficiency, suggesting that increased antibody evasion is not the reason for the current expansion of BA.2 in several countries.
79
Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic.
Inês Bártolo,Cheila Rocha,José Bartolomeu,António Gama,Rute Marcelino,Marlene Fonseca,Ana Verena Mendes,Marta Epalanga,Patrícia Cavaco Silva,Patrícia Cavaco Silva,Nuno Taveira,Nuno Taveira,Nuno Taveira +12 more
TL;DR: The extraordinary degree of HIV-1 group M genetic diversity and evolution in Angola may pose unprecedented challenges to diagnostic, treatment and prevention of HIV/AIDS infection.
61
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
Prerna Arora,Lu Zhang,Nadine Krüger,Cheila Rocha,Anzhalika Sidarovich,Sebastian R. Schulz,Amy Kempf,Luise Graichen,Anna-Sophie Moldenhauer,Anne Cossmann,Alexandra Dopfer-Jablonka,G. Behrens,Hans-Martin Jäck,Stefan Pöhlmann,Markus Hoffmann +14 more
TL;DR: All sublineages were comparably and efficiently neutralized by antibodies induced by BNT162b2 booster vaccination after previous two-dose homologous or heterologous vaccination.
54
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
Thanigaimalai Pillaiyar,Philipp Flury,Nadine Krüger,Haixia Su,Laura Schäkel,Elany Barbosa da Silva,Olga Eppler,Thales Kronenberger,Tianqing Nie,S Luedtke,Cheila Rocha,Katharina Sylvester,Marvin R I Petry,James H. McKerrow,Antti Poso,Stefan Pöhlmann,Michael Gütschow,Anthony J. O’Donoghue,Yechun Xu,Christa E. Müller,Stefan Laufer +20 more
TL;DR: The potent Sars-CoV-2 Mpro inhibitors also inhibited the Mpro of other beta-coronaviruses, including SARS- coV-1 and MERS-coV, indicating that they might be useful to treat a broader range of coronaviral infections.
51
Baseline susceptibility of primary HIV-2 to entry inhibitors.
Pedro Borrego,Rita Calado,José Maria Marcelino,Inês Bártolo,Cheila Rocha,Patrícia Cavaco-Silva,Manuela Doroana,Francisco Antunes,Fernando Maltez,Umbelina Caixas,Helena Barroso,Nuno Taveira +11 more
TL;DR: The reduced sensitivity of R5 variants to MVC indicates that the treatment of HIV-2-infected patients with MVC might require higher dosages than those used in HIV-1 patients, and should be adjusted to the disease stage.